SG11202004904XA - Binding molecules that specifically bind to tau - Google Patents

Binding molecules that specifically bind to tau

Info

Publication number
SG11202004904XA
SG11202004904XA SG11202004904XA SG11202004904XA SG11202004904XA SG 11202004904X A SG11202004904X A SG 11202004904XA SG 11202004904X A SG11202004904X A SG 11202004904XA SG 11202004904X A SG11202004904X A SG 11202004904XA SG 11202004904X A SG11202004904X A SG 11202004904XA
Authority
SG
Singapore
Prior art keywords
tau
specifically bind
binding molecules
molecules
binding
Prior art date
Application number
SG11202004904XA
Other languages
English (en)
Inventor
Constantin Apetri
Jaroslaw Juraszek
Harmke Verveen
Roosmarijn Janson
Berdien Siregar
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of SG11202004904XA publication Critical patent/SG11202004904XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202004904XA 2017-12-04 2018-12-04 Binding molecules that specifically bind to tau SG11202004904XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17205124 2017-12-04
PCT/EP2018/083451 WO2019110571A1 (en) 2017-12-04 2018-12-04 Binding molecules that specifically bind to tau

Publications (1)

Publication Number Publication Date
SG11202004904XA true SG11202004904XA (en) 2020-06-29

Family

ID=60569783

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004904XA SG11202004904XA (en) 2017-12-04 2018-12-04 Binding molecules that specifically bind to tau

Country Status (10)

Country Link
US (1) US20200369754A1 (zh)
EP (1) EP3720490A1 (zh)
JP (1) JP2021505142A (zh)
KR (1) KR20200094177A (zh)
CN (1) CN111447951A (zh)
AU (1) AU2018380765A1 (zh)
CA (1) CA3084098A1 (zh)
EA (1) EA202091350A1 (zh)
SG (1) SG11202004904XA (zh)
WO (1) WO2019110571A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105121465B (zh) 2013-03-13 2020-09-08 普罗塞纳生物科技公司 Tau免疫疗法
FI3452507T3 (fi) 2016-05-02 2022-12-15 Tau-immuunihoito
US10889638B2 (en) 2016-05-02 2021-01-12 Prothena Biosciences Limited Antibodies recognizing tau
WO2018204546A2 (en) 2017-05-02 2018-11-08 Prothena Biosciences Limited Antibodies recognizing tau
BR112021016947A2 (pt) 2019-03-03 2021-11-03 Prothena Biosciences Ltd Anticorpos que reconhecem tau
TWI832183B (zh) * 2019-08-06 2024-02-11 香港商新旭生技股份有限公司 結合至病理性tau種類之抗體及其用途
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023178241A2 (en) * 2022-03-16 2023-09-21 The Regents Of The University Of Colorado A Body Corporate Methods and compositions for disrupting tau aggregates using polyserine repeat sequences targeting exogenous proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE536417T1 (de) 1999-04-15 2011-12-15 Crucell Holland Bv Herstellung von rekombinanten proteinen in einer menschlichen zelle mit mindestens einem e1 adenovirus protein
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
PL2627672T3 (pl) * 2010-10-11 2018-11-30 Biogen International Neuroscience Gmbh Ludzkie przeciwciała anty-tau
KR20170023124A (ko) * 2014-06-26 2017-03-02 얀센 백신스 앤드 프리벤션 비.브이. 미세소관-연관 단백질 타우에 특이적으로 결합하는 항체 및 항원-결합 단편

Also Published As

Publication number Publication date
WO2019110571A1 (en) 2019-06-13
EP3720490A1 (en) 2020-10-14
KR20200094177A (ko) 2020-08-06
EA202091350A1 (ru) 2020-09-02
JP2021505142A (ja) 2021-02-18
CA3084098A1 (en) 2019-06-13
US20200369754A1 (en) 2020-11-26
CN111447951A (zh) 2020-07-24
AU2018380765A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
IL275510A (en) Specific antigen-binding molecules-ROR1
IL273631A (en) Special hpv molecules bind
IL263715A (en) lag-3 binding organs
IL274371A (en) Compounds that bind CD137 and PSMA
HK1252862A1 (zh) 結合cd45的抗體分子
SG11202004904XA (en) Binding molecules that specifically bind to tau
HK1252791A1 (zh) 具有經修飾的j鏈的結合分子
IL254223A (en) CD20 binding compounds and their uses
GB201612520D0 (en) Binding molecules
GB201702091D0 (en) Specific binding molecules
SG10202111844VA (en) Cxcr4 binding molecules
IL269394A (en) Antibodies bind to STEAP-1
HK1258317A1 (zh) 對asct2具有特異性的結合分子及其用途
IL269752B (en) fgfr3 binding molecules
GB201820446D0 (en) Antigen binding molecules that bind light
HRP20181700T1 (hr) Fascikl
GB201718735D0 (en) Bispecific molecules that bind to CD137 and PSMA
GB201508729D0 (en) Binding molecules